Kurs
-4,47%
Kurs
-4,47%
Open
11,55
High
12,29
Low
11,55
Close
11,78
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2026-03-05 | 06:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 06:00 | Kvartalsrapport 2025-Q3 |
| 2025-09-17 | 06:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | Årsstämma |
| 2025-06-10 | 06:00 | Kvartalsrapport 2025-Q1 |
| 2025-03-05 | 06:00 | Bokslutskommuniké 2024 |
| 2024-12-20 | - | Extra Bolagsstämma 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-06-27 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2024-06-26 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-26 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | Årsstämma |
| 2023-06-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-19 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2022-04-17 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-12-29 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-08 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2021-04-13 | - | Årsstämma |
| 2021-02-09 | - | Bokslutskommuniké 2020 |
| 2020-12-14 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-30 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-20 | - | Extra Bolagsstämma 2019 |
| 2019-06-27 | - | Årsstämma |
| 2019-06-03 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2018-07-02 | - | Split SOFTX 1:50 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-09-05 07:18:22
SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announced today the end of the Phase 1 clinical study of the SoftOx
Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx's antimicrobial
solution for treatment of chronic wounds.
"We would like to thank our study participants and the staff at DanTrials ApS.
SoftOx is looking forward to announcing the top line results in Q4 2022," said
Glenn Gundersen, Sr Medical Director of SoftOx.
SBE-01 is a first-in-human study investigating the safety, tolerability, and
antimicrobial efficacy of single and multiple doses of the SoftOx Biofilm
Eradicator (SBE) in patients with venous leg ulcers. In Phase 1b the company
treated the wounds once and twice daily over 5 days. The original study design
included three times daily administration for five days